替米沙坦對高血壓伴陣發性心房顫動患者房顫復發及C反應蛋白的影響_《華西醫學》

作者：

1 四川石油總醫院心內科（成都，610213），2 四川省遂寧市人民醫院心內科;

關鍵詞：

替米沙坦高敏C反應蛋白心房顫動

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

【摘要】目的 觀察替米沙坦對高血壓伴陣發性心房顫動患者房顫復發及對左心房內徑(LAD)、血清C反應蛋白(HsCRP) 的影響。方法 2007年6月-2008年12月陣發性房顫患者42例，隨機分為替米沙坦組和常規治療組各21例，分別于治療前、治療后12個月測定LAD、HsCRP水平，并隨訪治療后12個月時房顫復發次數。結果替米沙坦組房顫復發次數及LAD、HsCRP水平均低于常規治療組，兩組比較，有統計學意義(P lt;0.05)。結論替米沙坦能抑制高血壓伴陣發性房顫患者的左房重構，降低HsCRP水平，減少房顫復發。
【Abstract】 Objective To explore the effects of Telmisartan on recurrence of paroxysmal atrial fibrillation (PAF), left atrial direction (LAD) and serum levels of high sensitivity C reaction protein (HsCRP) in patients with hypertension combined with paroxysm atrial fibrillation. Methods A total of 42 PAF patients from June 2007 to December 2008 were randomly divided into Telmisartan group and routine treatment group. Before the treatment and 12 months after the treatment, LAD and HsCRP were detected,and the recurrence times of atrial fibrillation were counted 12 months after the treatment. Results The recurrence times of atrial fibrillation, and the levels of LAD and HsCRP were significant lower in Telmisartan group than that in the routine treatment group (P lt;0.05). Conclusion Telmisartan can reduce the recurrence of PAF and the levels of LAD and HsCRP.

引用本文： 王心群,鄧學軍. 替米沙坦對高血壓伴陣發性心房顫動患者房顫復發及C反應蛋白的影響. 華西醫學, 2010, 25(9): 1592-1593. doi: 復制

1.	Aviles RJ, Martin DO, Apperson HC, et al. Inflammation as a risk factor for atrialfibrillation[J]. Circulation, 2003, 108(24): 3006-3010.
2.	Healery JS, Morillo CA, Connooly SJ. Role of the reninangiotensin-aldosterone system in atrial fibrillation and cardiac remodeling[J]. Cur Opin Cardiol, 2005, 20(1): 31-37.
3.	Watanabe E, Arakawa T, Uchiyama T, et al. High sensitivity C reaction protein is predictive of succesful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion[J]. Int J Cardiol, 2006, 108(3): 346-353.
4.	Dernellis JM, Paneratou MP. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation[J]. Eur Heart J, 2004, 25(13): 1100-1107.
5.	Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: result from the Valsartan heart failure trial[J]. Am Heart J, 2005, 149(3): 548.
6.	Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation[J]. Cardiovas Res, 2002, 54(2): 230-246.

1. Aviles RJ, Martin DO, Apperson HC, et al. Inflammation as a risk factor for atrialfibrillation[J]. Circulation, 2003, 108(24): 3006-3010.
2. Healery JS, Morillo CA, Connooly SJ. Role of the reninangiotensin-aldosterone system in atrial fibrillation and cardiac remodeling[J]. Cur Opin Cardiol, 2005, 20(1): 31-37.
3. Watanabe E, Arakawa T, Uchiyama T, et al. High sensitivity C reaction protein is predictive of succesful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion[J]. Int J Cardiol, 2006, 108(3): 346-353.
4. Dernellis JM, Paneratou MP. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation[J]. Eur Heart J, 2004, 25(13): 1100-1107.
5. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: result from the Valsartan heart failure trial[J]. Am Heart J, 2005, 149(3): 548.
6. Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation[J]. Cardiovas Res, 2002, 54(2): 230-246.

《華西醫學》

替米沙坦對高血壓伴陣發性心房顫動患者房顫復發及C反應蛋白的影響

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《華西醫學》

替米沙坦對高血壓伴陣發性心房顫動患者房顫復發及C反應蛋白的影響

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料